ombitasvir + peginterferon alfa-2a + ribavirin

This drug is a **three-drug combination regimen** consisting of ombitasvir, peginterferon alfa-2a, and ribavirin. Ombitasvir is a direct-acting antiviral that functions as an NS5A inhibitor, interfering with hepatitis C virus (HCV) RNA replication. Peginterferon alfa-2a is a pegylated form of interferon alpha with immunomodulatory and antiviral properties. Ribavirin is a nucleoside analogue antiviral that inhibits viral RNA synthesis and mutagenesis. This regimen is designed for the treatment of **chronic hepatitis C virus infection**, specifically HCV genotype 1, including patients with prior treatment failure. The addition of ombitasvir to the established peginterferon alfa-2a plus ribavirin combination aims to increase efficacy through direct antiviral effects on HCV replication, combined with immunomodulation and nucleoside analogue action. Primary developers and studies on this combination involve AbbVie[1][3]. Safety data indicate common adverse events include fatigue, pruritus, nausea, and skin reactions[1].